# BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease

> **NCT07729995** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Luminary Therapeutics** · enrollment: 94 (estimated)

## Conditions studied

- Rheumatoid Arthritis (RA)
- Systemic Lupus Erthematosus (SLE)
- Dermatomyositis (DM)
- Systemic Sclerosis (SSc)

## Interventions

- **BIOLOGICAL:** LMY-922

## Key facts

- **NCT ID:** NCT07729995
- **Lead sponsor:** Luminary Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2030-03
- **Final completion:** 2030-03
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729995, "BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*